Mesoblast (OTC: MEOBF) CMO details initial option and share holdings
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Mesoblast Ltd director and Chief Medical Officer Eric Allen Rose has filed an initial Form 3 detailing his equity interests in the company. He directly holds 6,034,554 Ordinary Shares and an additional 714,720 Ordinary Shares, which are represented by American Depositary Shares.
He also reports multiple option awards over Ordinary Shares, including 820,000 underlying shares at an exercise price of $2.46 per share expiring in 2032, and other grants at exercise prices of $0.35, $0.36, $0.97, $1.01, and $1.81 with expirations between 2026 and 2031. Several recent option grants vest only if Mr. Rose achieves specified milestones.
Positive
- None.
Negative
- None.
Insider Trade Summary
18 transactions reported
Mixed
18 txns
Insider
ROSE ERIC ALLEN
Role
Chief Medical Officer,Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Option (right to buy) — 33,333 shares (Direct);
Ordinary Shares — 6,034,554 shares (Direct)
Footnotes (1)
- Such Ordinary Shares are represented by American Depositary Shares. Granted on October 16, 2023. Vesting is dependent on Mr. Rose achieving certain milestones. Granted on August 27, 2024. Vesting is dependent on Mr. Rose achieving certain milestones. Granted on August 26, 2025. Vesting is dependent on Mr. Rose achieving certain milestones.
FAQ
What does the Mesoblast (MEOBF) Form 3 for Eric Allen Rose show?
The Form 3 shows that Eric Allen Rose, Mesoblast’s Chief Medical Officer and director, has reported his existing holdings of Ordinary Shares and multiple option awards. It is an initial ownership statement, not a record of new purchases or sales.
What stock options are reported for Eric Allen Rose in the Mesoblast Form 3?
The filing lists several option grants over Mesoblast Ordinary Shares, including 820,000 underlying shares at a $2.46 exercise price expiring in 2032 and additional options at $0.35, $0.36, $0.97, $1.01, and $1.81 with expirations between 2026 and 2031.
Do Eric Allen Rose’s Mesoblast options depend on performance milestones?
Yes. The Form 3 footnotes state that option grants dated October 16, 2023, August 27, 2024, and August 26, 2025 vest only if Mr. Rose achieves specified milestones. This means some options become exercisable only when those conditions are satisfied.
Does this Mesoblast Form 3 indicate recent buying or selling by Eric Allen Rose?
No transactions are classified as buys or sells in the filing. All entries are reported as holdings with unknown transaction codes, so the document functions as a snapshot of Mr. Rose’s current share and option positions rather than recent trading activity.
How long do Eric Allen Rose’s Mesoblast options remain exercisable?
The option expirations disclosed range from 2026 through 2032. For example, options at a $1.81 exercise price expire in 2026, while the grant with an exercise price of $2.46 per share expires on August 25, 2032, if vesting conditions are met.